Emory has a BS from Vassar College and an MD from the Harvard-MIT Health, Science, Technology Program at Harvard Medical School. Prior to KPMG, Ryan worked at Morris and Morris, P.C. Barrie's 1911 novel. Jenna previously held roles as Senior Medical Writer and Analyst at Costello Medical Consulting. Cosmass academic research has been published in journals such as Cell, Science, and Nature. Nothing contained on the website constitutes investment advice, and the views expressed should not be taken as advice to buy, sell, or hold any security or as an endorsement of any security or company. Christinas previous experience includes Stem Cell Program Manager at the Broad Institute and Deputy Editor at Cell Stem Cell. Prior to joining RAVen, Joel was co-founder, President and Chief Scientific Officer at Jnana Therapeutics, a platform company focused on unlocking hard-to-drug targets. in Engineering Sciences in Bioengineering from Harvard University and a PhD in Medical Engineering and Medical Physics from the Harvard-MIT Health Sciences and Technology (HST) Program. His most recent role at Biogen was as Senior Vice President, U.S. Commercial, where he was the general manager of the MS, hemophilia, and SMA franchises. Elena's primary responsibility at RA Capital is to create competitive landscapes of biotechnology and planetary health. Cosmas Giallourakis is a Venture Partner at RA Ventures, focusing on new company creation. Michael has more than two decades of experience in immuno-oncology and immunology research in both large pharma and biotech settings. Ramin is an experienced clinical trialist and previously led global clinical development programs at Akebia Therapeutics and Gilead Sciences. Emilies primary responsibility at RA Capital is to manage current and potential investor relationships. Adison is an Executive Assistant RA Capital Management. In this episode Peter speaks with Dr. Wayne Shreffler, Director of the Food Allergy Center at Massachusetts General Hospital & Division Chief of Pediatric Allergy and Immunology at MassGeneral Hospital for Children. Previously, Zach covered the neurology, ophthalmology, and dermatology landscapes. She is a CPA. Prior to joining RA Capital, Mario was Associate Vice President for Advanced Research at Sanofi Pasteur and Head of the team executing a strategy for integrating influenza vaccine development with machine learning and antigen design. Prithviraj works on both public and private investments with a focus on Healthcare, Technology, and Services. Natalie holds a BA in Psychology from William Paterson University and a MA in Psychology from Seton Hall University. Raj is active in both public and private investments in companies developing drugs, medical devices, diagnostics, and research tools. He holds a JD from Northeastern University School of Law and a BS in Biology from Tufts University. The Kolchinskys came to the United States from Russia in 1981, when Peter was 4. James holds a BS in Journalism from Boston University and a JD from Boston College Law School. Within the last 20 years alone, PJ Hogan had a go with 2003's Peter Pan (a major, almost $100m-losing flop), Joe Wright tried again in 2015 with the more radical Pan (another massive failure . Previously, Jake covered solid tumor oncology landscapes. Age 46 / Jul 1976. After joining RA Ventures as Chief Development Officer, Ed built the development team, oversaw development of six compounds from discovery-stage through to clinical-stage, and led the formation of several new companies, including Lusaris Therapeutics. Her primary responsibility is leading and executing full cycle recruiting across all newcos and portfolio companies. After leaving Schrodinger in 2018, Soumya founded 3-Dimensional Consulting, a boutique Physics Based and Machine-Learning focused computational chemistry consulting firm that provides scientific support for early-stage drug discovery and company formation within various Boston-based venture firms including: Atlas Venture, 3rd Rock, MPM Capital, and RA Capital. Sadik Kassim is a scientist and executive with extensive experience in the biotechnology industry with a specific focus on cell and gene therapy bioprocessing and translational research. His responsibilities include managing the portfolios public equity positions, monitoring market, sector, and individual equity dynamics, and maintaining relationships with broker/dealer counterparties. He holds a BS in Biology from the College of William and Mary, where he studied the impact of ecological fragmentation on the prevalence of ticks and their bacterial pathogens. Tyler holds a BA in Finance from the University of Massachusetts, Amherst and a certificate in Interactive Design from Rhode Island School of Design. Ernesto Gonzalez is a Business Systems Manager at RA Capital. Ed has 30 years of experience in preclinical and clinical drug development, and in regulatory affairs for pharmaceutical and biotechnology companies. Nadim has 11+ years experience in commercializing drug discovery across diverse indications and modalities. Soumya has more than two decades of experience in structure-based drug design and molecular modeling both in the areas of small molecules and biologics across multiple target classes and indications. Soumya completed his postdoc at Brigham and Womens Hospital and held an Assistant Professor of Neuroscience role at Harvard Medical School Neurology Department where he contributed to the Harvard Neurodiscovery Centers (HNDC) academic drug discovery initiative as a modeler and drug hunter. David holds a BS in Economics with a minor in Business Administration from University of Colorado Boulder. Cristina Montero is an Associate Director within the TechAtlas division of RA Capital Management. Erich Scheller is the Director of the TechAtlas division of RA Capital Management. Cristina holds a BA in Molecular Biology with a minor in Business from Washington University in St. Louis, and a PhD in Microbiology and Molecular Genetics from Harvard University. Previously, Nate covered atopic dermatitis, psoriasis, dermatology, colorectal cancer, cancer diagnostics, and broader tools and diagnostics as a Senior Associate within RAs TechAtlas division. Matthew works on both public and private investments and serves as a Board Director for Cerebral Therapeutics, DTx Pharma, Emergence Therapeutics, Forge Biologics, Jnana Therapeutics, and Kira Pharmaceuticals. Join Peter Kolchinsky on his first episode of Future in Sight, a new podcast from FARE. Rez Halse is President of RAVen, also known as RA Ventures, RA Capitals company creation incubator. Tom has a BA in Business Administration from St. Anselm College and earned both his Chartered Financial Analyst and Chartered Alternative Investment Analyst designations. Andrews primary responsibility is to help guide internal software development to support competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. Garrett received a BS with honors from the California Institute of Technology while publishing his first paper with Dr. Paul H. Patterson, holds a PhD in Immunology from Stanford University, where he studied hematopoietic stem and progenitor cells with Dr. Irving L. Weissman, and completed his post-doctoral training at Childrens Hospital Boston/Harvard Medical School studying ES/iPSC specification to the hematopoietic fate with Dr. George Q. Daley. Dan Guglielmo is IT Operations Associate at RA Capital Management. By Matt Grobar. Henry has a BA in Biology & Economics from Dartmouth College. Sarah began her legal career with Foley, Hoag, & Eliot LLP. Angela has a BA in Pre-Medicine and French Studies from the University of Minnesota. His doctoral research focused on breast cancer metastasis. Previously, was a Research Analyst in the Kauwe lab at Brigham Young University. Alex is an Associate with the TechAtlas division of RA Capital Management. She received a B.Sc. Peter Kolchinsky was born in the United States of America. Candice previously worked as the Director of Executive Office and Administration at Flywire. Nate Davis is an Analyst on the Investment Team at RA Capital Management. In these commercial roles, he initiated innovative discovery deal structures with venture companies, research foundations, and large integrated deals with pharmaceutical companies. He also gained extensive legislative and public policy experience early in his career as a Legislative Aide to former United States Senator David Boren, and as a Domestic Policy Advisor to former Vice President Al Gore. He completed an internship in Internal Medicine and residency in Psychiatry at the University of Utah Health Sciences Center. "Too old," said a man in his 70s. Monica holds a BSc in Neuroscience and Pharmacology from the University of Toronto and a PhD in Cancer Biology from MIT. Maryann received her Bachelor of Science in English from Northeastern University. Ross has a BS in Biochemistry from University of Oregon and a PhD in Pharmacology & Molecular Sciences from Johns Hopkins University. Kyle also recently retired as a Colonel in the US Army Reserve after 24 years of service. Shannon's primary responsibilities are to manage the front desk and office facilities. Prior to Relay, she worked as an Executive Assistant at Bullhorn, Inc. Phi holds an Associate in Science Business Administration from Middlesex Community College. Angela Pontius is Vice President of Clinical Operations at RA Ventures (RAVen). Cristina holds a Bachelor of Arts in Biochemistry from Mount Holyoke College and a PhD in Cell Biology and Epigenetics from Cornell University and The Rockefeller University. Since 2002, he has been working in start-up pharma companies, including co-founding Thesan Pharmaceuticals and NeoKera, where he assumed responsibilities for all development activities, including regulatory affairs. Prithviraj comes to RA from CVS Health, where he was Director of HealthHUB Product Technology Strategy and Enablement. He holds a MS from Northeastern University and a BA from Hamilton College. She is on the Steering Committee for No Patient Left Behind, a non-profit focused on reforming American healthcare to make medicines affordable to patients and promote innovation. Priscilla has a B.S. Daphne Zohar is the founder and CEO of PureTech. He co-founded and runs the Boston-based investment firm RA Capital Management; writes and teaches about biomedical entrepreneurship and its potential to transform global health; serves on the boards of several public and private drug development companies; and lives in . He received his doctorate in Organic Chemistry from Ohio University, and was a Fellow and Instructor in Department of Medicine, Boston University School of Medicine. MarketScreener: Created by Investors for Investors! Dans primary responsibility at RA Capital is to identify compelling opportunities to help facilitate new company creation or investments in emerging seed-stage companies. RA Capital and CEO of Arcuate Therapeutics. This helps us to provide you with a good experience when you browse our website, and also allows us to improve our site. At Ra Pharma, Alonso held various leadership roles where he initiated and led the scientific efforts for the company in multiple preclinical and clinical programs; working in a wide set of therapeutic areas and using different molecular modalities. Previously, Shan Shan covered Orphan Heme, Orphan GOF, Vaccines, and various Gene Therapies as a Senior Associate. Andrew Levin is a Partner and Managing Director on the Investment Team at RA Capital Management and spearheads a drug discovery effort that has led to the formation of several new companies. Chris Caliri is the Chief Information Officer at RA Capital Management. All information is subject to change and may quickly become unreliable for various reasons, including changes in market conditions or economic circumstances. He worked previously as an Associate Managing Editor at EBSCO Health, and as a Medical Writer at IC Axon and Publicis Life Brands International. Tweet With huge thanks to RA Capital's Alex Martinez-Forte and Jacqueline Rhuda for extensive data analysis. Nadim completed his BS in Biology at Stony Brook University, received his PhD with Distinction in Microbiology at Columbia University, and was an NRSA Postdoctoral Fellow studying the cell biology of HCV in the laboratory of Nobel Prize winner Charles M. Rice at the Rockefeller University. Mariagrace Houllahan is an Executive Assistant at RA Capital Management. Receptionist and Facilities Administrator. Matt Beverly is a Senior Software Engineer at RA Capital Management. Largest investment: 7.9 million shares of Vor Biopharma worth $142 million at the time of its IPO . Prior to Acceleron, Habib held various leadership roles at Bayer AG during his ~22-year tenure with the company. He previously worked as a corporate attorney at Foley Hoag LLP and Cooley LLP. Prior to joining RAVen, Michael was the Executive Vice President and CMO at Point32Health, formed by the merger of Harvard Pilgrim Health Care and Tufts Health Plan. Ally coached Women's Lacrosse at Muhlenberg College in PA. In his career, Scott has worked to raise over $600 million in funding for ventures with which he has been directly involved as a founder or operating executive. Kaleen Sullivan is a Research Operations Manager at RA Capital Management. Kate's primary responsibility is to work with both the Legal and Compliance Teams in support of their programs. Ernestos primary responsibility at RA Capital is to coordinate various technology related initiatives across the company and oversee their initiation, planning, and execution. Anas primary responsibility is to conduct research and analysis for competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. Jess'sprimary responsibility is to direct a concerted effort to analyze, design, and shape internal and external narratives. Most recently, Ally spent over five years at Akebia Therapeutics (previously Keryx), where she held Commercial Team Administrator/Internal Meetings Specialist, Sales Team Administrator/Training Specialist and Senior Administrative Assistant roles. Sams primary responsibility is to help guide internal software development to support competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. She has twenty years of oncology experience with a strong focus on skin cancers, especially malignant melanoma. EXCLUSIVE : Robert Morgan's Talaria . James is admitted to practice law in the Commonwealth of Massachusetts. Alyssa previously worked as a Senior Scientist at Eagle Pharmaceuticals. Gunes Bozkurt is an Analyst on the Venture Team at RA Capital Management. A trained cardiologist, he has held academic faculty positions at the University of California, San Francisco (UCSF) and the University of Texas Southwestern Medical Center. Prior to her Managing Director role at NVF, Nandita held various positions at Novartis in Business Development and Licensing and as a key member of the Kymriah Global Program Team, helping to bring this novel cell therapy to market. She holds a BS in Corporate Finance & Accounting and an MBA from Salem State University. James was most recently the founder, Chief Executive Officer, and served as a Board Director for Imara, a public company developing therapies for sickle cell disease and -thallasemia. Anas previous experience includes Research Assistant positions at Massachusetts Eye and Ear Hospital, the Lupus Clinic/Renal Department at the BU Medical Center, and Harvard University Department of Molecular and Cellular Biology. Prior to Merck, he was a Partner with the Partners Innovation Fund, the corporate venture arm of Mass General Brigham hospital (formerly Partners HealthCare), where he invested in Seed/Series A therapeutics-focused companies. By accessing this website, you agree not to copy, reproduce, republish, upload, post, transmit, alter, or distribute, in any way, content or materials from this website in any manner inconsistent with the purposes for which it is offered without the prior written consent of RA Capital. In this role, he gained broad expertise across all phases of drug discovery, early development, and clinical research. Matt comes to RA from Localytics where he served as a Senior Software Engineer for the past two years. Milind Deshpande is a Venture Partner at RA Capital, and President & CEO of Nayan Therapeutics, a RA Capital portfolio company. He is an Enrolled Agent, admitted to practice before the IRS. Alex Martinez-Forte is an Analyst, Strategic Finance at RA Capital Management. Prior to RAVen, Scott was President and Managing Director of The Branta Group LLC, a healthcare company formation, capital investment, and strategic advisory firm known for taking an active management role with its clients and portfolio companies in the biotechnology, medical device, diagnostics, venture capital, and private equity sectors. Brigid's primary responsibility at RA is to lead investments in private companies that are developing innovative solutions to address climate change and environmental sustainability. Peter Kolchinsky is a father, scientist, investor, teacher, and author. This website is for informational purposes only and does not constitute an offer to provide investment advisory or other services by RA Capital Management, L.P. (RA Capital). Finally, they made it to the Boston. He is also an active member of the Big Brothers of Massachusetts Bay program. Ben holds a BS in Biology and an MS in Virology from the University of Nebraska, Lincoln, and a PhD in Cancer Biology from the Tufts University School of Medicine. Jaimie holds a BA in Biology Boston College, with Minors in Medical Humanities and Sociology, and a Master of Public Health from Boston University School of Public Health. In his doctoral research, he investigated clinically translatable treatments for musculoskeletal tissue repair using injectable hydrogels. and Novus Biologicals. in Biomedical Anthropology from the University of Pennsylvania. Emily Minkow is a Venture Partner at RA Ventures. Vanderpump Rules' Peter Madrigal's Age. Toms primary responsibility is to support all aspects of trade and treasury operations. Soumya obtained his PhD in X-ray Crystallography and Biophysics from the Indian Institute of Science while working as visiting research scholar at Rockefeller University. Prior to Localytics, Matt served as software engineer at Mathworks. Habib has earned his Director Professionalism Certificate from the National Association of Corporate Directors. Robert also led the Sequencing Operations and Technology Development groups at the Broad for over 12 years, implementing industrial process control methods, developing multiple generations of high-throughput DNA sequencing technologies, and establishing an agile learning culture in the organization. Prior to joining RA, Kathryn was SVP of Strategy at Energetic Insurance where she addressed regulatory-driven commercial lender limitations to enable financing for renewable energy and efficiency via financial insurance products. In this role he works closely with RAs Venture Team to evaluate various drug discovery platforms and initiate novel therapeutics programs. Sonias primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Prior to MassTech, Natalie held varying Administrative roles at Northeastern University, Framingham Public Schools, and Bright Horizons Family Solutions. Prior to RA, Dan spent three years in Systems Engineer and Technical Consultant roles at Withum Smith + Brown, where he provided cloud and hybrid implementation guidance for clients within industries such as healthcare, construction, and fitness. Prior to Citigroup, he held various accounting and analyst roles at EY, Morgan Stanley, BBH, and Deloitte. Walter Dauksher is a Junior Associate within the Planetary Health division of RA Capital Management. Prior to PwC, Brendan worked as Senior Tax Analyst for Highfields Capital Management LP and held tax and accounting positions at Citi and Investors Bank & Trust / State Street. Craig Randall is Assistant General Counsel at RA Capital Management and Counsel at RA Ventures, RA Capital's incubator for new companies. All rights reserved. Peter Pan has long been a character that audiences have held up a critical lens to, as the premise of an eternal boy who recruits isolated children naturally brings up some questions the more a person thinks about it. in Business Administration in Management with a Minor in Biology from UMass Amherst Commonwealth Honors College. Peter Kolchinsky, Ph.D. Brians primary responsibility at RA Capital is to conduct due diligence on biotechnology companies. Jesse has more than a decade of discovery research and management experience, from early discovery through preclinical development. Adison previously held posts as an Administrative Assistant and Office Manager at Dyer Brown Architects and as an Executive Assistant to the Principal and Office Manager at bKL Architecture. He holds a BA in Neuroscience with a minor in Molecular and Cellular Biology from Colorado College. Prior to joining biotech/pharma, she was a specialist in the corporate finance team at McKinsey & Co, focused on corporate transactions. Brendan has more than 18 years of experience as a tax professional. in Immunology from National Taiwan University College of Medicine, and a PhD in Biomedical Science from The Ohio State University. Joe holds a BS in Information Technology from UMass Lowell. He was a faculty member at the University of Rochester School of Medicine prior to joining Merck Research Laboratories in 2004. Prior to joining RAVen, Kat was a Partner at van den Boom & Associates where she provided accounting and finance services including new company formation through IPO and public company accounting support, SOX compliance implementation, and financial modeling to several public and private life science companies. Tess works on both public and private investments and serves on several company boards. His prior posts include Fund Accountant at Nautic Partners and HLM Venture Partners. He previously held roles as VP Product Manager - Data Services at Charles River Development (a State Street Company) and Senior Business Analyst in Capital Markets at Bain Capital Credit and State Street Global Exchange, DataGX. He holds a BA in History from University of Massachusetts, Amherst and a Master's of Urban Affairs from Boston University. Prior to these companies, James held senior research leadership roles in the gene and stem cell therapy companies Cell Genesys, Phylogix, and Somatix Therapy. Maryann Vigliotta is the Vice President of Operations and HR at RA Ventures (RAVen). Rez brings to RA over 20 years of experience working in the life-science industry.
St Bernard's Food Pantry,
Redbone Coonhound Rescue,
Articles P
